Organigram ($OGI) Stock Hub 2026: Revenue Up 49%, A C$105.5 Million Profit That Is Not Cash, And C$11.7 Million Left In The Bank

01 Executive Summary

Organigram Global Inc. is a Canadian cannabis producer headquartered in Moncton, New Brunswick, listed on both the Nasdaq and the Toronto Stock Exchange, with a fiscal year ending September 30. It sells recreational cannabis in Canada under brands including SHRED, Edison, Big Bag O’ Buds, BOXHOT, Tremblant, Collective Project, Monjour, Trailblazer and DEBUNK, and since April 2026 it also sells medical cannabis in Germany and neighbouring markets through Sanity Group, whose brands include Vayamed, avaay, ZOIKS, Endosane, VAAY and Grashaus.

The third fiscal quarter, covering the three months to June 30, 2026 and reported before the market opened on August 11, 2026, is the first period in which Sanity Group is consolidated for a full quarter, and the numbers change shape accordingly. Net revenue reached C$105.8 million against C$70.8 million a year earlier, an increase of 49%. The split was C$61.8 million recreational, 58% of the total, C$39.0 million medical, described by the company as mostly international, at 37%, and C$4.9 million of wholesale and other at 5%. A year ago the medical line was immaterial; over the nine months it went from C$1.8 million to C$40.4 million, and essentially all of that is Germany.

Profitability improved on the operating measures. Gross margin before fair value adjustments was C$38.8 million, 37% of net revenue, against C$22.4 million and 32%. Adjusted gross margin, which the company defines as net revenue less cost of sales before biological asset fair value effects and inventory provisions, was C$39.1 million or 37%, from 34%. Adjusted EBITDA reached C$13.4 million against C$5.7 million, an increase of 136%, at a 13% margin against 8%.

Reported net income was C$105.5 million against a C$6.3 million loss a year earlier, and basic earnings per share were C$0.781. That figure requires immediate qualification, and the company supplies it: the increase was primarily attributable to a fair value gain of C$105.8 million on the preferred shares issued to British American Tobacco. Strip that single non-cash accounting item out and the quarter is roughly breakeven at the net line rather than the most profitable in company history.

The balance sheet is where the tension sits. Cash, restricted cash and short-term investments fell to C$11.7 million at June 30, 2026 from C$84.4 million at the September 30, 2025 year end, a decline of 86%. Unrestricted cash was C$10.9 million. Operating activities used C$4.3 million in the quarter and C$27.1 million over the nine months, against C$6.1 million used in the prior nine-month period. Free cash flow over the nine months was negative C$29.0 million. What sustains the position is a credit facility with ATB Financial of up to C$60 million, of which C$37.4 million in revolving and operating lines remained undrawn, all maturing April 15, 2029, bringing total available liquidity to C$49.1 million.

Guidance was reaffirmed on revenue and cut on cash. The company continues to expect fiscal 2026 net revenue to exceed C$350 million, with adjusted EBITDA and adjusted gross margin exceeding fiscal 2025, and it now expects modest negative free cash flow for the full fiscal year, while continuing to expect positive free cash flow in the fourth quarter.

02 The Profit That Is Not Cash

A headline reading that Organigram earned C$105.5 million in a quarter on C$105.8 million of revenue would describe a company with a hundred per cent net margin, which no cannabis producer has ever had. The explanation is a single line, and the company states it plainly: the increase was primarily attributable to the fair value gain of C$105.8 million on preferred shares.

Why that gain exists

British American Tobacco holds preferred shares in Organigram whose conversion ratio accretes at 7.5% a year, and that accretion stops once BAT’s effective stake reaches a 49% threshold. The instrument is carried at fair value, so its value moves with the estimated time remaining before that threshold is crossed. During the third quarter Organigram issued further preferred shares to BT DE Investments Inc., a wholly owned BAT subsidiary, taking BAT’s effective holding to about 48%. That issuance shortened the estimated remaining period before the 49% threshold, the fair value of the liability fell sharply, and the fall was recorded as a gain in the income statement.

Two consequences follow. The first is that no cash entered the business as a result of the gain: it is a remeasurement of an instrument the company issued. The second is that the mechanism is symmetrical and can reverse, since the same estimate that produced a gain this quarter can produce a loss in another if the assumptions move the other way.

What the operating result looks like without it

Adjusted EBITDA of C$13.4 million is the company’s own measure of operating performance, and it excludes, among many other items, the change in fair value of derivative liabilities and preferred shares. It rose 136% year on year, which is a genuine improvement produced by higher revenue, better gross margin and the consolidation of Sanity Group. Below that line the business still carries depreciation, amortisation, share-based compensation, financing costs and the working capital demands of a larger operation, and the cash flow statement shows the result: C$4.3 million of operating cash used in the quarter and C$27.1 million over the nine months.

03 What The Company Actually Is Today

Until April 2026 Organigram was a Canadian company selling Canadian recreational cannabis, with small international shipments and a United States hemp-derived beverage experiment. Two decisions changed that: the acquisition of Sanity Group, which closed on April 15, 2026, and the wind-down of the United States hemp business. The result is a company with two centres of gravity, one in Moncton and one in Berlin.

The Canadian business

Recreational cannabis in Canada produced C$61.8 million of net revenue in the quarter, 58% of the total, and C$165.9 million over nine months against C$155.1 million a year earlier. The brand portfolio spans value flower with Big Bag O’ Buds and SHRED, premium with Edison and Tremblant, vapes with BOXHOT, beverages and edibles with Collective Project and Monjour. Growth in this segment is single-digit; it is a mature and price-competitive market.

The German business

Sanity Group contributed revenue of EUR 25.5 million between April 1 and June 30, 2026, its first full quarter inside Organigram. It operates in the German medical cannabis market with expansion into Poland, the Czech Republic, the United Kingdom and Switzerland, and the company puts its German market share at approximately 10% on internal estimates. That single acquisition is why total revenue grew 49% while the Canadian recreational line grew in single digits.

What is being closed

The United States hemp-derived THC business, built around the happly brand and the Collective Project acquisition effective March 31, 2025, is being wound down. The reason is legislative: section 781 of the Continuing Appropriations and Extensions Act of 2026 takes effect on November 12, 2026 and restricts the products that business sold. The company’s investment in OBX was written down to nil during the third quarter. That is a clean and dated example of regulatory risk converting into a write-off in a single quarter.

Australia and the export track

Ten vape and edible product lines were launched into the Australian medical market during the second fiscal quarter with distribution planned through more than four thousand pharmacies, and by the third quarter the majority of the branded portfolio was commercially available with prescription sales having begun. EU-GMP certification of the Moncton site, which would allow direct export into European medical markets, remained in progress at the time of reporting, with additional documentation supplied to the regulator in April 2026 and no timeline given.

04 The Quarter In Detail

Revenue

Net revenue of C$105.8 million against C$70.8 million is an increase of C$35.0 million or 49%. Over the nine months net revenue is C$229.1 million against C$179.1 million, up C$50.0 million or 28%, and gross revenue before excise duty over the same nine months is C$335.6 million against C$279.8 million, up 20%. The company does not publish a gross revenue figure for the quarter in isolation, only the nine-month total, and the same applies to free cash flow.

Margins

Gross margin before fair value adjustments was C$38.8 million, 37% of net revenue, against C$22.4 million and 32%. Adjusted gross margin was C$39.1 million or 37%, against C$24.2 million and 34%. Over the nine months adjusted gross margin is C$81.4 million or 36%, against C$60.4 million and 34%. Two things push the percentage up at once: the German medical business carries a different margin structure to Canadian value flower, and the Canadian operation has taken cost out.

Adjusted EBITDA and what it excludes

Adjusted EBITDA of C$13.4 million against C$5.7 million is a 136% increase, at a 13% margin against 8%. Over nine months it is C$19.5 million against C$12.0 million, up 63%. The definition is long and excludes, among other things, investment income net of financing costs, tax, depreciation and amortisation and impairment, share-based compensation, changes in the fair value of contingent consideration and of derivative liabilities and preferred shares, research and development expenditure net of depreciation, unrealised gains on biological assets, inventory provisions, government subsidies, legal provisions, the incremental fair value of inventory sold from acquisitions, ERP implementation costs, transaction costs, share issuance costs and the provision for expected credit losses. A measure that excludes that many items is useful for comparing operations over time and is not a proxy for cash generation, which is why the cash flow statement is the check.

Below the operating line

Net income of C$105.5 million against a C$6.3 million loss is dominated by the C$105.8 million preferred share fair value gain examined in section 02. Basic earnings per share were C$0.781 and diluted C$0.773, against C$(0.047) both ways a year earlier. Over the nine months net income is C$124.6 million against C$13.2 million, with basic earnings per share of C$0.910.

05 Canadian Market Share, Read With Its Footnotes

Organigram states that at the end of the third fiscal quarter it held the number one market share position in the Canadian recreational cannabis market, and the filing attributes that to multiple sources named as Hifyre, Weedcrawler, provincial boards and internal modelling, as at June 2026.

The category detail comes from the corporate update of July 20, 2026. Organigram was number one in flower with 12.5%, number one in vapes with 14.5% and number two in pre-rolls with 7.3%. Those three categories together account for more than 86% of Canadian recreational retail sales, so leadership across them is the substance of the number one claim rather than a marketing line. The company also reported year-on-year share gains of 3.1 percentage points in beverages and 3.3 points in concentrates.

The number that is less flattering

Total Canadian recreational share at the end of June was 11.1%, down 0.4 percentage points year on year and up about 100 basis points sequentially against May. The direction over twelve months is therefore slightly negative, and the improvement is a one-month sequential recovery after a decline in the vape segment during the second fiscal quarter. The company describes that decline as stabilised in June, with all-in-one vape share improving by roughly one percentage point against the previous month and distribution of the new all-in-one portfolio expanded to every Canadian province except Nova Scotia and Quebec.

A footnote worth keeping: the 11.1% figure appears in the July 20 corporate update and is not repeated verbatim in the August 11 management’s discussion and analysis, which confirms the number one position with the sources named but without a percentage attached. The category percentages in the July update do not carry an explicit source citation, unlike the aggregate claim in the August filing.

Why share matters more than usual here

Canadian recreational cannabis is a market where price competition has compressed margins for years and where regulated retail data is available monthly, so share is both visible and fought over. The company’s own market projection, drawn from March 2026 internal modelling using BDSA and Hifyre data, is that Canadian recreational sales reach C$6.1 billion in calendar 2028. Holding eleven per cent of a market that size is a different proposition to holding eleven per cent of today’s, and it is the argument for building scale now.

06 Sanity Group: The Acquisition That Changed The Numbers

Organigram agreed to acquire Sanity Group GmbH under a share purchase agreement dated February 18, 2026 and closed the transaction on April 15, 2026, taking one hundred per cent of the outstanding shares it did not already hold. The upfront purchase price was EUR 107.3 million, composed of EUR 78.0 million in cash and EUR 29.3 million in shares, with a potential earn-out of up to a further EUR 113.8 million.

The cash portion was funded by two things that arrived in the same week: a private placement completed on April 15, 2026 with a wholly owned subsidiary of British American Tobacco for EUR 40.3 million, which the company states was the equivalent of C$65.2 million, and a C$20 million non-revolving term facility drawn under the ATB Financial credit agreement.

What it brought

Sanity Group generated EUR 25.5 million of revenue between April 1 and June 30, 2026, its first full quarter inside the group, and holds approximately 10% of the German market on the company’s internal estimates. It sells medical cannabis in Germany with expansion into Poland, the Czech Republic, the United Kingdom and Switzerland, under brands including Vayamed, avaay, ZOIKS, Endosane, VAAY and Grashaus. Excluding goodwill and intangibles, the acquired business brought approximately C$60.9 million of current assets, C$64.7 million of total assets, C$23.7 million of current liabilities and C$76.9 million of total liabilities at the acquisition date.

What it cost beyond the price

An earn-out of up to EUR 113.8 million is a contingent liability that will be settled if the acquired business performs, which means the better Sanity does, the more Organigram pays. Max Konrad Narr was appointed to the board of directors in connection with the acquisition for a twelve-month earn-out period ending March 31, 2027. And the working capital demands of consolidating a larger, faster-growing business are the reason the company gave for cutting its free cash flow outlook: higher working capital requirements associated with increased scale and business activity.

The German regulatory question

German rules on reimbursement changed during the period. Organigram’s assessment is that the impact is not material because reimbursement-based sales represent approximately one per cent of Sanity’s total revenue. That is a specific and checkable claim, and it is the right one to monitor, because the German medical market has moved quickly in both directions since prescription rules were liberalised.

07 Cash, Debt And Liquidity

Cash, restricted cash and short-term investments were C$11.7 million at June 30, 2026 against C$84.4 million at September 30, 2025, a decline of 86%. In a separate section of the same filing the company discloses unrestricted cash of C$10.9 million at June 30, 2026 against C$28.2 million at September 30, 2025. The two figures cover different perimeters, both are disclosed, and reading either one without its label produces a wrong answer.

Against that, operating activities used C$4.3 million in the quarter, where the prior-year quarter provided C$14.6 million, and used C$27.1 million over the nine months against C$6.1 million used a year earlier. Free cash flow over the nine months was negative C$29.0 million against negative C$23.9 million, with the difference between operating cash flow and free cash flow accounted for by C$1.9 million of property, plant and equipment purchases, sharply lower than the C$17.8 million spent in the comparable prior period. Capital spending is not what consumed the cash; working capital and the acquisition were.

The debt side

Long-term debt was carried at C$21.0 million at June 30, 2026, with contractual cash flows of C$22.4 million, and consists principally of the C$20 million non-revolving term facility used to part-fund the Sanity acquisition. The full credit agreement with ATB Financial provides up to C$60 million: the C$20 million term facility, a C$30 million revolving facility and a C$10 million operating facility, all maturing April 15, 2029. C$37.4 million of the revolving and operating lines remained undrawn, and the company puts total liquidity including the facilities at C$49.1 million.

What this means in practice

A company consuming roughly C$9 million of operating cash a quarter with C$11.7 million on the balance sheet and C$37.4 million of undrawn facilities is not in immediate difficulty, but it has moved from a position where cash covered years of operation to one where the credit line is load-bearing. The company’s own answer is the fourth quarter: it continues to expect positive free cash flow in the three months to September 30, 2026, which it describes as more representative of the underlying cash-generation trajectory of the business. That expectation is the single most checkable claim in the release, and the annual results will settle it.

08 British American Tobacco, The Shareholder That Shapes The Accounts

British American Tobacco is described by Organigram as its largest institutional shareholder, and the relationship is older and deeper than a shareholding. A Product Development Collaboration dated March 10, 2021 established a Centre of Excellence at the Moncton campus, jointly staffed and jointly funded: in the third quarter BAT incurred C$0.4 million and Organigram C$1.1 million of collaboration expense, and over nine months C$1.8 million and C$3.4 million respectively.

Between 2021 and 2026 BAT made three strategic investments in Organigram for total gross proceeds of approximately C$410 million. The company states those proceeds funded the collaboration, research and development, international initiatives including the Sanity Group purchase, and general corporate purposes. The most recent tranche was the private placement of EUR 40.3 million, equivalent to C$65.2 million, completed on April 15, 2026 alongside the Sanity closing.

The mechanics that produced this quarter’s profit

BAT’s holding is structured through preferred shares, 49,204,022 of them outstanding at both June 30 and August 7, 2026, convertible in certain scenarios into a total of 51,823,554 common shares once the accumulated conversion value is included. That conversion ratio accretes at 7.5% a year, and the accretion stops when BAT’s stake reaches a 49% threshold. Following the third-quarter issuance BAT’s effective interest reached approximately 48%.

Because the instrument is carried at fair value and its value depends on the estimated time before the threshold is crossed, moving closer to 49% reduced the estimated remaining period and cut the fair value sharply. The reduction was recorded as a C$105.8 million gain. That is the whole of the reported quarterly profit, and it originates in the capital structure rather than in the sale of cannabis.

What a 48% shareholder means for everyone else

An investor holding common shares in Organigram is a minority alongside a strategic holder approaching half the company under an instrument that mechanically increases its share over time until a defined ceiling. That has two readings, and both are defensible. It is a source of non-dilutive-to-strategy funding and industrial partnership that few competitors have. It is also a structure in which the largest holder’s economics and the common shareholder’s economics are not identical, and in which the path to any change of control runs through one party.

09 Capital Structure

The company-declared share data is given at two dates. Common shares issued and outstanding were 140,975,357 at June 30, 2026 and 141,006,497 at August 7, 2026. Preferred shares were 49,204,022 at both dates. Options were 2,685,508 and 2,676,758, warrants 4,450,500 at both dates, top-up rights 5,895,258 and 5,873,533, restricted share units 3,201,500 and 3,165,110, and performance share units 1,911,107 at both dates. Total fully diluted shares were 208,323,252 at June 30 and 208,287,527 at August 7.

The gap between 141.0 million common shares and 208.3 million fully diluted is the structure of this company in one comparison: roughly a third of the fully diluted count sits outside the common shares, and most of that is the BAT preferred instrument. Any valuation built on the common share count alone understates the claims on the business.

Total shareholders’ equity was C$485.5 million at June 30, 2026 against C$349.1 million at September 30, 2025, an increase of 39% driven by the quarter’s accounting gain and the shares issued for Sanity. Total assets were C$820.3 million against C$562.2 million, up 46%, reflecting the acquisition. Non-current financial liabilities were C$97.4 million against C$76.4 million.

10 Guidance, In The Company’s Own Words

The outlook section of the August 11 filing does three things at once, and the third is easy to miss between the first two.

It reaffirms revenue: Organigram continues to expect fiscal 2026 net revenue to exceed C$350 million, with adjusted EBITDA and adjusted gross margin exceeding fiscal 2025 performance. With C$229.1 million booked over nine months, that implies a fourth quarter above C$120 million, which would be a further sequential increase on the C$105.8 million just reported. The consolidation of Sanity for a full quarter is the mechanical reason that is plausible.

It cuts the cash outlook: the company is updating its fiscal 2026 free cash flow outlook to reflect higher working capital requirements associated with its increased scale and business activity, and now expects modest negative free cash flow for the full fiscal year. That is a downgrade of a previously more positive expectation, delivered in the same release as record revenue.

And it keeps one commitment intact: the company continues to expect positive free cash flow in the fourth quarter of fiscal 2026, which it believes is more representative of the underlying cash-generation trajectory of the business. With C$11.7 million of cash on hand, that fourth quarter is the claim that carries the most weight.

No numerical guidance for fiscal 2027 appears in any of the August or July disclosures. The company’s market projection, sourced to March 2026 internal modelling using BDSA and Hifyre data, is that Canadian recreational sales reach C$6.1 billion in calendar 2028; that is a market estimate, not company guidance.

11 Governance, Controls And The Open Regulatory Items

The material weakness

Organigram disclosed in its Form 40-F for the fiscal year ended September 30, 2025 a material weakness in internal control over financial reporting, relating to management review controls designed to ensure the completeness and accuracy of complex spreadsheets used in the biological asset and inventory valuation processes. The August 11 filing confirms that internal control over financial reporting was not effective at June 30, 2026, that remediation is in progress, and that the company aims to complete it before the end of fiscal 2026.

The location of the weakness is what makes it worth watching rather than filing away. Biological assets and inventory valuation are precisely where a cannabis producer’s judgement has the largest effect on reported margin, and inventory rose 39% to C$147.8 million over the nine months while the controls covering its valuation were acknowledged as not effective. That is not an allegation of error; it is a description of where the risk of one would sit.

The United States wind-down

Section 781 of the Continuing Appropriations and Extensions Act of 2026 takes effect on November 12, 2026, 365 days after the enactment of the underlying legislation in November 2025, and restricts hemp-derived THC products. Organigram is winding down that business and wrote its investment in OBX down to nil during the third quarter. A separate and unrelated proceeding, the administrative hearing on cannabis rescheduling before the United States Drug Enforcement Administration, had a closing argument brief deadline of August 17, 2026; that is a sector-wide regulatory process rather than a company event.

Management and board

James Yamanaka is chief executive officer. Max Konrad Narr joined the board in connection with the Sanity Group closing, for a twelve-month earn-out period ending March 31, 2027. No other management or board changes appear in the July and August disclosures.

EU-GMP

Certification of the Moncton facility to European good manufacturing practice standards, which would permit direct supply into European medical markets from Canadian production rather than through acquired local supply, remained in progress with additional documentation provided to the regulator in April 2026 and no timeline disclosed.

12 Market Data And How This Stock Trades

$OGI traded at $1.16 on the Finviz reading of August 11, 2026, up 10.5% on results day, on volume of about 19.7 million shares against a market capitalisation near $158 million. The stock is dual-listed on the Nasdaq and the Toronto Stock Exchange, and Finviz classifies the company under healthcare, specialty and generic drug manufacturers, with Canada as the country of domicile.

Three features define the trading profile. It is a sub-two-dollar stock, which brings the mechanical consequences that come with that price band: percentage moves are large, retail participation is high and institutional mandates that exclude low-priced securities do not participate. Volume of 19.7 million shares against 141.0 million common shares outstanding means roughly fourteen per cent of the common count changed hands in one session, which is not a normal day. And the reported figures are in Canadian dollars while the Nasdaq quote is in United States dollars, so a reader comparing a C$105.8 million revenue line to a $158 million market value is comparing two currencies unless the conversion is made explicit.

One reference point, which is not a valuation: the market capitalisation of about $158 million converts to roughly C$220 million at the August 11 rate, against nine-month net revenue already booked of C$229.1 million and full-year guidance above C$350 million. Cannabis producers have traded at a fraction of revenue for several years, and that comparison describes the sector’s rating rather than this company’s merit.

13 Retail Sentiment

The block below is a snapshot of the Stocktwits stream with its timestamp. These are the opinions of retail traders and non-professional investors, not of analysts, and they measure attention and crowding rather than research.

14 The Case Made By Those Who Are Positive

What follows is the argument as its holders make it, not a Merlintrader view.

Scale is arriving and it shows in the margin. Net revenue up 49%, adjusted gross margin from 34% to 37%, adjusted EBITDA up 136% to C$13.4 million on a 13% margin. Those are operating improvements, not accounting ones, and they came in the first quarter of the enlarged group rather than after a year of integration.

The German business is real revenue, not a promise. Sanity Group produced EUR 25.5 million in the quarter with approximately ten per cent of the German market, and the German medical market is expanding while Canadian recreational is not. Owning distribution there is worth more than exporting into it.

Category leadership in the parts of Canada that matter. Number one in flower at 12.5% and in vapes at 14.5%, number two in pre-rolls at 7.3%, in categories that are more than 86% of the recreational market, plus year-on-year share gains in beverages and concentrates. That is a portfolio position, not a single hit product.

A strategic shareholder who keeps writing cheques. Approximately C$410 million from British American Tobacco across three investments since 2021, the most recent in April 2026 funding an acquisition rather than covering losses, plus a joint research centre. Few competitors have a partner of that size and none has one that has funded them at that scale.

The cash outflow has an identifiable cause. Capital expenditure fell from C$17.8 million to C$1.9 million over the nine months, so the drain is working capital tied to a bigger business and an acquisition, not overspending on facilities. Management expects the fourth quarter to be free cash flow positive, and inventory of C$147.8 million converts to cash if it sells.

Revenue guidance implies acceleration. More than C$350 million for the year against C$229.1 million booked in nine months means a fourth quarter above C$120 million, which the company reaffirmed on the same day it published the third quarter.

15 The Case Made By Those Who Are Sceptical, And The Red Flags

The profit is an accounting entry. Reported net income of C$105.5 million rests on a C$105.8 million fair value gain on the preferred shares held by the largest shareholder. No cash arrived, the mechanism can reverse, and a headline that reports the profit without the cause misdescribes the quarter.

Cash fell 86% in nine months. From C$84.4 million to C$11.7 million on the combined measure, and from C$28.2 million to C$10.9 million on unrestricted cash. Operations consumed C$27.1 million over the nine months, against C$6.1 million in the prior comparable period, and the quarter itself consumed C$4.3 million where the year-earlier quarter generated C$14.6 million.

The free cash flow outlook was cut on the day of record revenue. The company now expects modest negative free cash flow for the fiscal year, attributing it to higher working capital requirements. A business whose working capital demand rises faster than its cash generation as it scales has a structural issue, not a timing one, until proven otherwise.

Canadian share is down year on year. Total recreational share of 11.1% at the end of June is 0.4 percentage points lower than a year earlier. The sequential recovery of about 100 basis points against May follows a decline in the vape segment during the second fiscal quarter. One month of improvement is not a trend.

Internal controls over financial reporting are not effective. The material weakness disclosed in the fiscal 2025 Form 40-F concerns management review controls over the complex spreadsheets used in biological asset and inventory valuation, and it was still open at June 30, 2026 with remediation targeted before the fiscal year end. Inventory grew 39% to C$147.8 million in the same period.

The earn-out is a liability that grows with success. Up to a further EUR 113.8 million is payable on Sanity Group if the acquired business performs, against a company holding C$11.7 million of cash and C$37.4 million of undrawn credit.

Regulatory risk already converted into a write-off once this year. The United States hemp-derived THC business is being wound down because of section 781, effective November 12, 2026, and the OBX investment went to nil in the third quarter. The same category of risk applies to German reimbursement rules and to Canadian excise and pricing policy.

A shareholder approaching half the company on an accreting instrument. BAT’s effective stake is about 48%, the conversion ratio accretes at 7.5% a year until 49%, and the fully diluted count of 208.3 million is 48% above the 141.0 million common shares outstanding.

16 Scenario Framework

The two paths below describe what would have to happen, and they carry no probabilities and no price levels.

The variable that separates the two is not revenue growth, which the acquisition has already delivered, but cash conversion. The checkpoints the company has published are: the Digital Investor Session in late September 2026, date not yet fixed; the fourth fiscal quarter ending September 30, 2026, in which management expects positive free cash flow; the fiscal 2026 annual results that follow it and which will carry the full-year revenue outcome against the C$350 million guidance; the remediation of the material weakness, targeted before the end of fiscal 2026; and November 12, 2026, when the United States hemp restriction takes effect.

17 Bottom Line

Two accurate and opposite descriptions of Organigram can be held at the same time. The first is a company that grew net revenue 49% to C$105.8 million in a single quarter, lifted adjusted gross margin to 37%, more than doubled adjusted EBITDA to C$13.4 million, holds the number one share position in Canadian flower and vapes, added a German business generating EUR 25.5 million a quarter, and has a strategic shareholder that has put approximately C$410 million into it since 2021. The second is a company whose reported profit is a non-cash revaluation of that shareholder’s instrument, whose cash and short-term investments fell 86% in nine months to C$11.7 million, which consumed C$27.1 million of operating cash over the same period, which cut its free cash flow outlook on the day it reported record revenue, and which is carrying C$147.8 million of inventory under valuation controls it has told the market are not effective. Both descriptions come from the same filing.

What is verified. Third fiscal quarter net revenue of C$105,782 thousand against C$70,792 thousand, up 49%, split C$61.8 million recreational, C$39.0 million medical and C$4.9 million wholesale and other. Gross margin before fair value adjustments of C$38.8 million at 37%, adjusted gross margin C$39.1 million at 37%, adjusted EBITDA C$13.4 million at a 13% margin. Net income of C$105,538 thousand including a C$105,783 thousand fair value gain on preferred shares, basic earnings per share C$0.781. Cash, restricted cash and short-term investments of C$11,667 thousand at June 30, 2026 against C$84,420 thousand at September 30, 2025; unrestricted cash C$10,851 thousand. Operating cash flow of negative C$4,297 thousand in the quarter and negative C$27,070 thousand over nine months; nine-month free cash flow negative C$28,965 thousand. Long-term debt carried at C$20,973 thousand, C$37,432 thousand undrawn on facilities maturing April 15, 2029, total liquidity C$49.1 million. 141,006,497 common shares and 208,287,527 fully diluted at August 7, 2026, with BAT at approximately 48% effective. Sanity Group acquired April 15, 2026 for EUR 107.3 million upfront plus up to EUR 113.8 million of earn-out, contributing EUR 25.5 million of revenue in the quarter.

What is not verified. Gross revenue and free cash flow for the third quarter in isolation, because the company publishes both only on a nine-month basis. The source of the category market share percentages in the July 20 update, which are not footnoted in the way the aggregate claim in the August filing is. Whether the 11.1% total share figure from July still held at the quarter end, since the August filing states the number one position without repeating the percentage. Fiscal 2027 guidance, which does not exist in any of the current disclosures. The exact date of the Digital Investor Session. And the analyst consensus, since no individual note could be confirmed with both house and exact date.

The dates that settle the question: late September 2026, for the second Digital Investor Session and its capital allocation section; September 30, 2026, the end of the fiscal fourth quarter in which management expects positive free cash flow and by which it aims to have remediated the material weakness; the fiscal 2026 annual results that follow, carrying the full-year revenue outcome against guidance above C$350 million; and November 12, 2026, when the United States hemp-derived THC restriction takes effect.